GOVX

GeoVax Labs, Inc.

Tremor tracks 2 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

A key executive is leavingSince Nov 6, 2026+14.8

Trials

GOVXGeoVax, Inc.
15Calm
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Running, no new patientsPhase 263 patientsMain results: Dec 31, 2026
GOVXGeoVax, Inc.
15Calm
Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer
FinishedPhase 1/210 patientsMain results: Dec 29, 2023

Key executives leaving

From the last 12 months of the company's SEC reports.

Nov 6, 2026
“Dodd was terminated as President and Chief Executive Officer of the GeoVax Labs, Inc. (the “ Company ”), effective immediately.”
Read the filing ↗

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

0 sales (0 not pre-planned) · 0 purchases

No insider sales or purchases in the last 6 months.

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.